The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 118.00
Bid: 117.00
Ask: 119.00
Change: 0.00 (0.00%)
Spread: 2.00 (1.709%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 118.00
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re ECO Animal Health and The Pirbright Institute sign second poultry vaccine development licencing deal.

11 Sep 2019 07:00

 

11 September 2019

ECO Animal Health Group plc

(AIM: EAH)

ECO Animal Health and The Pirbright Institute sign second poultry vaccine development licencing deal

ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, is pleased to announce that it has entered into a second worldwide exclusive research partnership with The Pirbright Institute, United Kingdom, to develop another novel vaccine for use in chickens.

Innovative technologies developed at Pirbright will use a Marek’s disease virus vector to express multiple protective components against the economically important poultry viral diseases of infectious bursal disease virus (IBDV), Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV) which cause significant systemic and respiratory damage.

The global poultry biologicals market is worth c. $2.3 billion and forecast to grow with a CAGR of 5-6%. The Marek’s disease, IBDV, NDV and ILTV segments are collectively worth c. $470 million.

Professor Venugopal Nair, Head of Avian Viral Diseases at the Pirbright Institute, states: “The novel vaccine will have the potential to induce simultaneous protection against Marek’s disease as well as the other major diseases caused by IBDV, NDV and ILTV that threaten poultry health and production worldwide.”

Commenting Marc Loomes, CEO of ECO Animal Health Group plc, said: “We are delighted to have partnered with the Pirbright Institute again to develop another novel vaccine for use in chickens. The use of the Marek’s disease vector in this technology is a significant advancement over other recombinant vaccines and will help widen the potential use of this vaccine in broilers and in breeding stock.”

Enquiries:

 

 

 

ECO Animal Health Group plc

 

Marc Loomes, CEO

020 8447 8899

 

 

N+1 Singer (Nominated Advisor and Joint Broker)

020 7496 3000

Mark Taylor

 

Alex Bond

 

 

 

Peel Hunt (Joint Broker)

020 7418 8900

James Steel

 

Dr Christopher Golden

 

 

 

IFC Advisory

020 3934 6637

Graham Herring

 

Miles Nolan

 

Zach Cohen

 

 

 

The Pirbright Institute

0148323 2441

About ECO Animal Health Ltd

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

About The Pirbright Institute

The Pirbright Institute is a world leading centre of excellence in research and surveillance of virus diseases of farm animals and viruses that spread from animals to humans. It receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), and works to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005895/en/

Copyright Business Wire 2019

Date   Source Headline
5th Mar 20187:00 amBUSRegulatory Approval
1st Feb 20181:33 pmBUSBlock listing Interim Review
1st Feb 20181:24 pmBUSTotal Voting Rights
23rd Jan 20183:37 pmBUSDirector/PDMR Shareholding
22nd Jan 20187:00 amBUSRegulatory Approval
5th Jan 20187:00 amBUSCirc re. Change of Nominated Adviser
19th Dec 20177:00 amBUSRegulatory Approval
13th Dec 20177:00 amBUSRegulatory Approval
6th Dec 20177:00 amBUSHalf-year Report
1st Dec 20177:00 amBUSDirectorate change
2nd Nov 20173:20 pmBUSBlock listing Interim Review - Replacement
25th Sep 20173:42 pmBUSHolding(s) in Company
22nd Sep 20178:53 amBUSHolding(s) in Company
20th Sep 20178:04 amBUSAGM Statement
4th Sep 20173:12 pmBUSTotal Voting Rights
23rd Aug 20178:30 amBUSDirector/PDMR Shareholding
21st Aug 20177:00 amBUSRegulatory Approval
15th Aug 20174:48 pmBUSDirector/PDMR Shareholding
14th Aug 20177:00 amBUSRegulatory Approval
1st Aug 20177:00 amBUSCirc re. Block listing return
1st Aug 20177:00 amBUSTotal Voting Rights
24th Jul 20177:00 amBUSRegulatory Approval
19th Jul 201711:05 amBUSDoc re. Block Listing Application
11th Jul 201710:11 amBUSHolding(s) in Company
11th Jul 201710:04 amBUSHolding(s) in Company
3rd Jul 20172:26 pmBUSNotice of AGM
30th Jun 20172:56 pmBUSDirector/PDMR Shareholding
30th Jun 20177:00 amBUSFinal Results
5th Jun 20177:00 amBUSRegulatory Approval
15th May 20177:00 amBUSTrading Statement
13th Mar 20179:32 amBUSHolding(s) in Company
2nd Feb 20178:29 amBUSHolding(s) in Company
20th Jan 20173:59 pmBUSHolding(s) in Company
20th Jan 20173:56 pmBUSHolding(s) in Company
12th Jan 20173:05 pmBUSDirector/PDMR Shareholding
9th Jan 20177:00 amBUSRegulatory Approval
19th Dec 201610:42 amBUSDirector/PDMR Shareholding
12th Dec 20167:00 amBUSHalf-year Report
5th Dec 20167:00 amBUSRegulatory Approval
2nd Nov 201610:06 amBUSHolding(s) in Company
1st Nov 201610:23 amBUSCirc re.Appointment of Joint Broker
31st Oct 201612:55 pmBUSDirector/PDMR Shareholding
31st Oct 20169:00 amBUSHolding(s) in Company
19th Oct 20167:00 amBUSRegulatory Approval
13th Oct 20164:24 pmBUSDirector/PDMR Shareholding
6th Oct 20167:46 amBUSDirector/PDMR Shareholding
28th Sep 20163:44 pmBUSDirector/PDMR Shareholding
16th Sep 201612:47 pmBUSAGM Statement
16th Sep 20167:00 amBUSAGM Statement
15th Sep 20163:57 pmBUSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.